Navigation Links
Shortages of Potassium Iodide as Radiation Panic Drives Demand
Date:3/28/2011

DENVER, March 28, 2011 /PRNewswire/ -- The Japanese nuclear crisis has caused a surge in the demand of potassium iodide, causing shortages not only in Japan, but as far away as California, western Canada, and even southeastern Russia. Although potassium iodide does not provide generalized radiation protection because it only shields the thyroid, manufacturers and pharmacies are being bombarded with orders as the radiation hysteria mounts.

A new and superior product, known as the BioShield Radiation Pill, could restore calm to worried residents in affected areas. Scientists at Premier Micronutrient Corporation have developed this pill as the first ever that is proven to protect DNA from damage caused by radiation. The product was originally developed at the request of the Marine Corps after 9/11 to protect military personnel from the adverse effects of radiation they might encounter while fighting in the Middle East. Research conducted with the Department of Defense, NASA, and prominent universities has demonstrated effectiveness in addressing radiation-induced oxidative stress.

Dr. James Ehrlich was on the team that developed this groundbreaking pill. Invite this engaging and knowledgeable guest to answer:

  • Should all residents near nuclear plants have the BioShield pill in case of a radiation emergency?
  • Is this pill safe for young children?
  • How does the BioShield pill work differently from potassium iodide?
  • How long after exposure can this pill provide protective benefits?
  • Is this pill available without a prescription?

CREDENTIALS: Dr. James Ehrlich is a Clinical Associate Professor at the University of Colorado and an Adjunct Assistant Professor in the department of medicine at the George Washington University Medical Center. He is the medical director of Early Detection Technologies, LLC, which advises on best practices involving biomarkers, imaging technologies, and radiation protection. Involved in atherosclerosis research at two medical schools, Dr. Ehrlich is a founding member of the Society of Atherosclerosis Imaging, a co-founder of the Society of Cardiovascular CT, and he created the Society for Responsible Preventive Imaging. He is head of the medical advisory board of U.S. Preventive Medicine and is on the board of Premier Micronutrient Corporation with a particular focus on biologic radiation protection. Dr. Ehrlich is a co-author of a multimedia CD called The Physician's Guide to Coronary Imaging. He has appeared on over 200 TV and radio programs nationwide.

CONTACT: James Ehrlich, M.D., (303) 808-6470 (CO); earlydetectdoc@gmail.com; http://www.bioshieldpill.com and http://www.premiermicronutrient.com

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE Premier Micronutrient Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. New Study Shows Nu-Tek's Modified Potassium Chloride Improves Yields in Meat Processing
2. 50,000 Potassium Iodide Pills Donated to Japan
3. Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials
4. New Radiation-Blocking Medical Garments Introduced at RSNA Meeting in Chicago : Demron-M Technology Provides Total Protection in a Lightweight, Durable, Flexible Fabric
5. Parion Sciences Receives NIH Biodefense Grant to Study Novel Methods for Mitigating Radiation-Induced Lung Injury
6. Trinitas Comprehensive Cancer Center Now Offering Cancer Patients Faster, Ultra-Precise Radiation Using New RapidArc Technology
7. Oregon Health & Science University Knight Cancer Institute Enhances Patient Care With Monaco(R) Radiation Treatment Planning System
8. Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial
9. New near-field radiation therapy promises relief for overheating laptops
10. Dutch Medical Equipment Producer Nucletron Strengthens Leading Position in Cancer Radiation Therapy Market
11. Accuray to Showcase CyberKnife Treatment Planning Capabilities at Preeminent Radiation Oncology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... BioMedGPS announces expanded coverage of SmartTRAK ... module, US Hemostats & Sealants. , SmartTRAK’s US Market for Hemostats and Sealants ... sealants and biologic sealants used in surgical applications. BioMedGPS estimates the market will ...
(Date:10/12/2017)... , ... October 12, 2017 ... ... has launched Rosalind™, the first-ever genomics analysis platform specifically designed for life ... Named in honor of pioneering researcher Rosalind Franklin, who made a major ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... any gene in its endogenous context, enabling overexpression experiments and avoiding the use ... with small RNA guides is transformative for performing systematic gain-of-function studies. , ...
(Date:10/11/2017)... USA (PRWEB) , ... October 11, 2017 , ... ComplianceOnline’s ... take place on 7th and 8th June 2018 in San Francisco, CA. The Summit ... as well as several distinguished CEOs, board directors and government officials from around the ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):